# Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression

> **NCT03606395** · PHASE1 · COMPLETED · sponsor: **Navitor Pharmaceuticals, Inc.** · enrollment: 80 (actual)

## Conditions studied

- Treatment Resistant Depression

## Interventions

- **DRUG:** NV-5138
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03606395
- **Lead sponsor:** Navitor Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-06
- **Primary completion:** 2019-06-09
- **Final completion:** 2019-07-07
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2019-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03606395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03606395, "Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03606395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*